HWM
AKRO

Hemington Wealth Management’s Akero Therapeutics AKRO Stock Holding History

Hemington Wealth Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$0 Buy
+7
New +$339 ﹤0.01% 1519

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hemington Wealth Management's AKRO Position: Q3 2025 in Review

Hemington Wealth Management opened a new position in Akero Therapeutics (AKRO) in Q3 2025: 7 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1519 among its holdings.

265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Hemington Wealth Management held 7 shares of Akero Therapeutics worth $0 as of Q3 2025.
  • Akero Therapeutics was a new Hemington Wealth Management position in Q3 2025.
  • Akero Therapeutics made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1519 holding.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.